Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06455371
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-12
First Post:
2024-01-10
Brief Title:
Patient-centered Dosage of Levothyroxine
Sponsor:
University Hospital of North Norway
Organization:
University Hospital of North Norway
Study Overview
Official Title:
Patient-centered Decision Support Tool for Levothyroxine Dosage
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing Because dosage adjustment normally takes several months the investigators have developed a decision support tool DST that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice that is dosage adjustment every 2 months The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment patient reported outcome measures and ability to work
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None